CN107495383A - One kind relaxes bowel complex prebiotics and preparation method and application - Google Patents
One kind relaxes bowel complex prebiotics and preparation method and application Download PDFInfo
- Publication number
- CN107495383A CN107495383A CN201710714607.XA CN201710714607A CN107495383A CN 107495383 A CN107495383 A CN 107495383A CN 201710714607 A CN201710714607 A CN 201710714607A CN 107495383 A CN107495383 A CN 107495383A
- Authority
- CN
- China
- Prior art keywords
- parts
- prebiotics
- inulin
- polydextrose
- oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 80
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 75
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 40
- 229920001202 Inulin Polymers 0.000 claims abstract description 39
- 229940029339 inulin Drugs 0.000 claims abstract description 39
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 37
- 239000001259 polydextrose Substances 0.000 claims abstract description 37
- 229940035035 polydextrose Drugs 0.000 claims abstract description 37
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 37
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 36
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 36
- 206010010774 Constipation Diseases 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 19
- 235000013402 health food Nutrition 0.000 claims abstract description 6
- 239000002131 composite material Substances 0.000 claims description 42
- 230000002040 relaxant effect Effects 0.000 claims description 42
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 36
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000013325 dietary fiber Nutrition 0.000 abstract description 17
- 230000000968 intestinal effect Effects 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 16
- 210000003608 fece Anatomy 0.000 abstract description 7
- 230000036186 satiety Effects 0.000 abstract description 3
- 235000019627 satiety Nutrition 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract description 2
- 230000029142 excretion Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 16
- 230000013872 defecation Effects 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920002670 Fructan Polymers 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003871 intestinal function Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- 244000298479 Cichorium intybus Species 0.000 description 2
- 235000007542 Cichorium intybus Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- 229960001571 loperamide Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001495180 Arthrospira Species 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000519999 Stachys Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Relaxed bowel complex prebiotics and preparation method and application the present invention relates to one kind, the complex prebiotics are made up of the component of following parts by weight：30 80 parts of inulin, 20 60 parts of polydextrose, 2 10 parts of stachyose, 2 10 parts of FOS.4 kinds of prebioticses selected by the present invention, dispensing is reasonable, dosage science, can promote to wriggle from increase enteron aisle mechanical stimulus, shortens the excrement time, increase satiety, reduces the many-sides such as intestinal pH, prevention or relief of constipation.A variety of prebiotics compoundings can avoid the effect inferior position of the single dietary fiber such as enteron aisle effect unification, defecating feces excretion is weak, enteron aisle is easily uncomfortable, constipation tolerance.The complex prebiotics can be directly as terminal food, also can be as the dispensing of food or health food.
Description
Technical Field
The invention relates to the field of food, in particular to a composite prebiotic for relaxing bowel and a preparation method and application thereof.
Background
Constipation (constipation) is a common condition, mainly manifested by decreased frequency of defecation, dry and hard stools, and/or difficulty in defecation. A decrease in the number of bowel movements means fewer than 3 bowel movements per week. The difficult defecation comprises the labor waste, difficult defecation, incomplete defecation, time-consuming defecation and the need of manipulation for assisting defecation. The prevalence rate of chronic constipation is on the rise with dietary structure changes, faster pace of life and psychosocial factors. The prevalence rate of constipation of common people of adults in China is 3.19-11.6%, the total prevalence rate of constipation of old people is 11.5%, and the prevalence rate of constipation above 70 years old is 11.7-19.5%.
Although constipation does not directly cause death and endanger life, the constipation still cannot be slightly harmful to human bodies, can cause pain and reduce comfort, and becomes an important disease affecting the life quality of modern people. Patients with constipation often have abdominal distension, increased anus exhaust, dysphoria and other discomfort, and the retention of excrement and excessive absorption of toxins in the intestinal cavity can cause headache, dizziness, inappetence, insomnia and even damage to the memory and thinking ability; moreover, when the force is applied, the pressure in the abdominal cavity and the intracranial pressure can be increased, and the cerebrovascular rupture is easily induced. Meanwhile, constipation increases afterload of the heart, and there is a risk of inducing a cardiac infarction.
At present, a plurality of medicines, health-care foods and common foods for relaxing bowels are available on the market, wherein some products are added with chemical medicines or Chinese herbal medicines with strong effects, which are often accompanied with side effects of different degrees and are not good for human health after being eaten for a long time; and some products have the problems of unobvious defecation effect, single component, easy discomfort of intestinal tracts, easy tolerance and the like. Therefore, a product with natural raw material sources and good effect of relaxing bowel is urgently needed.
Disclosure of Invention
In order to solve the above problems, the present invention aims to provide a composite prebiotic for relaxing bowel, a preparation method thereof and an application thereof. The composite prebiotics for relaxing bowel has reasonable ingredients, scientific dosage, convenient taking, safety, effectiveness and good taste; can be taken for a long time. In addition, the product of the invention has good compliance in taking, thereby ensuring the treatment effect. The composite prebiotics for relaxing bowel can prevent or relieve constipation from multiple aspects of increasing intestinal tract mechanical stimulation, promoting peristalsis, shortening excrement time, increasing satiety, reducing intestinal tract pH and the like. The complex of multiple prebiotics can avoid the disadvantages of single dietary fiber such as single intestinal function, weak bowel relaxing function, easy discomfort of intestinal tract, constipation tolerance and the like.
The technical scheme of the invention is as follows:
composite prebiotics capable of relaxing bowel is composed of the following components in parts by weight: 30-80 parts of inulin, 20-60 parts of polydextrose, 2-10 parts of stachyose and 2-10 parts of fructo-oligosaccharide.
Preferably, the intestine-moistening and bowel-relaxing compound prebiotics consists of the following components in parts by weight: 40-60 parts of inulin, 30-50 parts of polydextrose, 5-10 parts of stachyose and 5-10 parts of fructo-oligosaccharide.
Further preferably, the intestine-moistening and bowel-relaxing compound prebiotics consists of the following components in parts by weight: 48-50 parts of inulin, 30-40 parts of polydextrose, 5-10 parts of stachyose and 5-10 parts of fructo-oligosaccharide.
Furthermore, the total weight of the composite prebiotics for relaxing bowel is 100 parts.
In a specific embodiment of the invention, the intestine-moistening and bowel-relaxing composite prebiotics consists of the following components in percentage by weight: 50% of inulin, 30% of polydextrose, 10% of stachyose and 10% of fructo-oligosaccharide.
In another specific embodiment of the invention, the composite prebiotics for relaxing bowel comprises the following components in percentage by weight: 48.4% of inulin, 38.6% of polydextrose, 6.5% of stachyose and 6.5% of fructo-oligosaccharide.
In another specific embodiment of the invention, the composite prebiotics for relaxing bowel comprises the following components in percentage by weight: inulin 50%, polydextrose 40%, stachyose 5% and fructo-oligosaccharide 5%.
The invention also provides a preparation method of the composite prebiotics for relaxing bowel, which can be prepared by taking the raw materials according to the proportion by the conventional method in the field and uniformly mixing the raw materials. Generally, the raw materials can be uniformly mixed by adopting an equivalent incremental method and using a three-dimensional V-shaped mixer for mixing for about 5-10 min.
The invention also provides a preparation containing the composite prebiotics for relaxing bowel.
Furthermore, the preparation also contains auxiliary materials and/or additives used in the fields of food and health-care food; alternatively, the formulation further comprises a pharmaceutically acceptable carrier.
The preparation can be prepared by adding adjuvants, additives, carriers, etc. commonly used in food field, health food field or pharmacy, such as carrier, excipient, diluent, disintegrating agent, aromatic, colorant, sweetener, such as microcrystalline cellulose used as excipient and/or disintegrating agent.
The formulation may be in various conventional forms in the art, such as tablets, capsules, granules, tabletted candies, and the like. For example, the composite prebiotics for relaxing bowel can be directly filled into capsules to prepare capsules; or granulating, drying, and making into tablet.
The composite prebiotics and the preparation thereof have good effects of relaxing bowel, and can be used for preventing constipation and intestinal diseases in various age groups; it can also be used for treating constipation, preferably habitual constipation and senile constipation.
The composite prebiotics and the preparation thereof for relaxing bowel can be directly used as terminal food and can also be used as an ingredient of food or health food.
The invention also comprises the application of the composite prebiotics or the preparation thereof for relaxing bowel to prepare food, health care products or medicines for relaxing bowel.
The raw materials of the invention are all available on the market.
The inulin is from chicory, meets the quality requirement of inulin in new resource food (No. 5 in 2009 of Ministry of health), and has an inulin content of more than or equal to 86%.
The polydextrose meets the national standard GB 25541-2010, and the content of the polydextrose is more than or equal to 90 percent.
The stachyose meets the industrial standard QB/T4260-.
The fructo-oligosaccharide conforms to the national standard GB/T23528-2009, and the content of the fructo-oligosaccharide is more than or equal to 95%.
Prebiotics are non-digestible food ingredients that selectively stimulate the growth and activity of specific intestinal bacteria and are beneficial to the health of the host. The prebiotics has effects of promoting intestinal probiotic flora proliferation, improving intestinal flora health, relieving constipation, and enhancing immunity. Some non-or indigestible oligosaccharides in the water-soluble dietary fiber, such as fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, soybean oligosaccharide, stachyose, raffinose, isomalto-oligosaccharide, etc. In addition, polysaccharides such as inulin, resistant starch, dextran, etc. are also included. Some algae can also be used as prebiotics such as spirulina, arthrospira, etc., and vegetables, Chinese herbal medicines, wild plants, etc. in natural plants can also be used as prebiotics.
Inulin (lunlin) is a mixture of fructose polymers composed of short-and medium-long chain β -D-fructan (fructan) and fructosyl (fructosyl) units linked by β 2-1 glycosidic linkages, the degree of polymerization usually being a mixture of 2-60 fructose units. Inulin as prebiotics and water-soluble dietary fiber can not be digested and decomposed by various digestive enzymes, and is fermented by intestinal flora in colon, so as to reduce intestinal pH, shorten intestinal transport time, increase feces volume, increase feces water content, feces frequency and quality, and improve constipation. Multiple double-blind random control experiments show that 15-20g of inulin can improve intestinal function and relieve constipation; can also promote the health of the digestive system by stimulating the growth of beneficial bacteria in the colon, thereby improving the intestinal microecological balance; in addition, inulin can promote calcium absorption, thereby maintaining the toughness of bones. Inulin is approved as a new resource food in China, the eating amount is less than or equal to 15g/d, and the inulin can be used for various foods except infant food.
Polydextrose (polydextrose) is a polysaccharide of randomly cross-linked glucose comprising all glycosidic linkages such as alpha and beta (1-2), beta (1-3), beta (1-4), beta (1-6) glycosidic linkages, and predominantly beta (1-6) glycosidic linkages, having an average degree of polymerization greater than 12 and a molecular weight greater than 2000. Polydextrose as a water-soluble dietary fiber can shorten the emptying time of food in stomach, promote the secretion of digestive juice, facilitate the digestion and absorption of nutrient substances, shorten the time of feces passing through intestinal tract, promote the movement of intestinal tract, and enhance the osmotic pressure of colon, so as to dilute the concentration of harmful substances in stomach and intestine and promote them to be discharged out of body. According to the literature report, the consumption amount of polydextrose in the population test is about 8-12 g. In addition, glucose is an effective prebiotic, and after being taken into human body, the prebiotic is beneficial to the propagation of beneficial bacteria (bifidobacteria and lactobacilli) in intestinal tract, and inhibits harmful bacteria such as clostridium and bacteroides; it also has effects in promoting mineral absorption and regulating blood lipid. The polydextrose as dietary fiber ingredient of health food can be directly administered in the form of capsule, tablet, oral liquid, granule, etc., with a dosage of 5-15 g/d. The recommended dosage of prebiotics is 4-12g/d effective in improving intestinal function
Fructooligosaccharides (FOS), also called oligofructose or fructo-oligosaccharide, are a mixture of short-chain and medium-and long-chain beta-D-fructans (fructans) and fructosyl (frucosyl) units connected by beta-2, 1 glycosidic bonds to form a degree of polymerization of 2-9. The fructo-oligosaccharide is mainly derived from plants such as chicory, onion, banana, garlic and leek. The fructo-oligosaccharide can be decomposed and fermented by intestinal flora to produce organic acid, lower intestinal pH, stimulate colon movement, and change the condition of diluting feces and promoting defecation. A plurality of clinical tests show that the fructo-oligosaccharide can improve the defecation effect of infants and the elderly. The fructo-oligosaccharide can stimulate the growth of beneficial bacteria in colon, thereby improving intestinal microecological balance, and inhibiting the generation of harmful substances such as amine, hydrogen sulfide, indole, phenol, etc., to promote the health of digestive system. In addition, it also has mineral absorption promoting and dental caries resisting effects.
Stachyose is the most rarely-available tetrameric oligosaccharide in prebiotics, and is a tetrasaccharide consisting of 1 molecule of alpha-glucose, 1 molecule of beta-fructose and 2 molecules of alpha-galactose, and the simple structure is expressed as fructose-glucose-galactose. It is functional oligosaccharide which is naturally present in the plant of stachys of Labiatae and can obviously promote the multiplication of beneficial flora in human intestinal tract, and is known as natural super strong bifidus factor. Generally, 0.5-3g of the product can promote the proliferation of Bifidobacterium and Lactobacillus in intestinal tract. Compared with other oligosaccharides, stachyose has the outstanding advantages of pure nature, definite structure, good stability, low dosage and no side effect, and is water-soluble dietary fiber with natural property. As a single prebiotic, stachyose can proliferate bifidus factor at a rate 40 times faster; stachyose can improve gastrointestinal function by using as soluble dietary fiber and increasing Bacillus bifidus, shorten food retention time in intestinal tract, increase water content, and inhibit growth of putrefying bacteria. The human body is lack of alpha-D-galactosidase for hydrolyzing stachyose, so that stachyose is not easy to digest, can be directly utilized by probiotics such as bifidobacterium and the like in the large intestine of human, promotes the growth and the reproduction of beneficial bacteria such as bifidobacterium and the like, improves intestinal flora, and further relieves intestinal diseases such as diarrhea, constipation, colitis and the like.
The invention provides the composite prebiotics which is safe and reliable and has the function of relaxing bowel based on the functional characteristics and effective dose of the 4 prebiotics and can be used for preventing or improving constipation in various age groups, and all components are natural substances beneficial to human bodies, so that no side effect is generated.
The invention selects 4 common prebiotics, namely inulin, polydextrose, fructo-oligosaccharide and stachyose, wherein the inulin, polydextrose and fructo-oligosaccharide can also be used as water-soluble dietary fibers. The functional sugar prebiotics have various types and complex structures, the basic chemical composition of the prebiotics depends on the composition of each monosaccharide molecule, the monosaccharide composition and the composition are different, the polymerization degree is different, the physicochemical property is different, and the physiological effect is also very different. The advantages of the compounding of various prebiotics can be complemented, and the action disadvantage of single prebiotics is avoided.
The advantages of the composite prebiotics of the invention are as follows:
1. the polymerization degree range is wide: the formula contains prebiotics or water-soluble dietary fibers with different polymerization degrees, monosaccharide (stachyose), oligosaccharide (fructo-oligosaccharide) and polysaccharide (polydextrose and inulin), on one hand, the prebiotics or the water-soluble dietary fibers can play an all-round role in the whole intestinal tract, on the other hand, gradient utilization is formed, a more lasting effect is brought, and intestinal tract side effects caused by rapid fermentation of small-molecular prebiotics, such as flatulence and diarrhea, are avoided.
2. The prebiotics are abundant in variety: the formula contains 4 prebiotics, and can prevent or relieve constipation from multiple aspects such as increasing intestinal tract mechanical stimulation, promoting peristalsis, shortening feces time, increasing satiety, reducing intestinal tract pH and the like. Can avoid the disadvantages of single dietary fiber such as single function of intestinal tract, weak function of relaxing bowels, easy discomfort of intestinal tract, constipation tolerance, etc.
3. The total amount of dietary fiber is sufficient: the fructo-oligosaccharide, polydextrose and inulin in the formula can be used as prebiotics and water-soluble dietary fiber. According to the report of the condition of residents and chronic diseases in 2012, the intake of dietary fiber of each standard person in China is 10.8g/d, and the suitable intake of the dietary fiber is 25-30g/d, so that the daily intake of the composite prebiotics is 10-20g, the recommended dosage is about 15g, and the deficiency of daily dietary fiber is supplemented.
4. The invention also discovers that the 4 prebiotics have synergistic effect in the aspect of treating constipation, and the treatment effect of the prebiotics is obviously better than that of one or more prebiotics used independently.
5. The solubility and the palatability of the product are greatly improved.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention. The examples do not show the specific techniques or conditions, according to the technical or conditions described in the literature in the field, or according to the product specifications. The reagents or instruments used are conventional products available from regular distributors, not indicated by the manufacturer.
The following sources of raw materials were used:
inulin (> 86%), cosusca corporation, belgium;
polydextrose (greater than or equal to 90%), bowling BioBand GmbH;
stachyose (type P70), beijing food science and technology ltd;
fructo-oligosaccharide (not less than 95%), Quantum Kogaku (China) biological products Ltd.
Example 1
A composite prebiotics for relaxing bowel comprises the following components: 500g of inulin, 300g of polydextrose, 100g of stachyose and 100g of fructo-oligosaccharide.
The preparation method comprises the following steps: weighing the raw materials according to the proportion, uniformly mixing (using a three-dimensional mixer), granulating by adopting a boiling one-step granulator, and finishing in a granulator (80-100 meshes) to obtain the feed.
Recommended daily amount is 15 g/d.
Example 2
A composite prebiotics for relaxing bowel comprises the following components: 484g of inulin, 386g of polydextrose, 65g of stachyose and 65g of fructo-oligosaccharide.
The preparation method comprises the following steps: the same as in example 1.
Recommended daily amount is 15 g/d.
Example 3
A composite prebiotics for relaxing bowel comprises the following components: 500g of inulin, 400g of polydextrose, 50g of stachyose and 50g of fructo-oligosaccharide.
The preparation method comprises the following steps: the same as in example 1.
Recommended daily amount is 15 g/d.
Example 4
A capsule for loosening bowel to relieve constipation is prepared by: 1000g of the composite prebiotics for relaxing bowel in the embodiment 1 is taken to be prepared into capsules, and each capsule contains 0.5g of the composite prebiotics for relaxing bowel.
Example 5
A chewable tablet for loosening bowel to relieve constipation is prepared by the following steps: 1000g of the composite prebiotics for relaxing bowel in the embodiment 2 is taken, mixed with magnesium stearate with the weight of 0.6-1.0 percent, and then pressed into 0.5g of chewable tablets by a tablet press.
Example 6
A granule for loosening bowel to relieve constipation is prepared by: 1000g of the composite prebiotics for relaxing bowel in the embodiment 3 is taken, sieved and mixed, added with proper amount of water to prepare soft materials, granulated by a one-step granulator, dried, finished and sieved, canned and bagged, and each bag is 15 g.
Comparative example 1
A composite prebiotic differing from example 1 only in that inulin is not included.
Comparative example 2
A composite prebiotic differing from example 1 only in that no polydextrose is included.
Comparative example 3
A complex prebiotic differing from example 1 only in that it does not comprise stachyose and fructooligosaccharides.
Comparative example 4
A complex prebiotic differing from example 1 only in that inulin was replaced by an equal amount of galactooligosaccharide.
Experimental example 1 bowel relaxing effect experiment
1. Materials and methods
1.1 Experimental animals and groups
Male Kunming mice with the weight of 18-22 g are selected for experiments, and are randomly divided into 13 groups according to the weight, and each group comprises 12 mice, namely a blank control group, a model control group, a composite prebiotics dry preparation group for relaxing bowel prepared in examples 1-3, a composite prebiotics dry preparation group prepared in comparative examples 1-4, a chrysanthemum powder dry preparation group, a polydextrose dry preparation group, a stachyose dry preparation group and a fructooligosaccharide dry preparation group. 1.2 dose selection
Examples 1-3 the intervention group dose was designed according to the daily recommended dose of 15g/d, the mouse dose was designed according to 10 times the human recommended dose, and the adult body weight was measured as 60kg, i.e. 2.5 g/kg; comparative examples 1-4 the intervening group dosages were 1.25g/kg, 1.75g/kg, 2g/kg, 2.5g/kg, respectively; the formulation of inulin, polydextrose, stachyose and fructo-oligosaccharide in the preparation is designed according to the formulation of example 1, and the dosages are 1.25g/kg, 0.75g/kg, 0.25g/kg and 0.25g/kg respectively.
2. Experimental methods
Referring to the evaluation method of bowel relaxing function in health food inspection and evaluation technical specifications (2003 edition), the bowel relaxing composite prebiotics prepared in examples 1-3, the composite prebiotics prepared in comparative examples 1-4, inulin, polydextrose, stachyose and fructo-oligosaccharide are evaluated for bowel relaxing effect by small intestine propulsion experiments.
After 14d of continuous administration of the test substance, the mice in each group were fasted for 20 hours. The blank control group is subjected to intragastric administration by distilled water, and the model control group and the test substance intervention group are subjected to intragastric administration by loperamide with the concentration of 8 mg/kgBW. After loperamide is given for 0.5 hour, the blank control group and the model control group are given ink for gastric lavage, the test object intervention group is given ink containing a test object for gastric lavage, the cervical vertebra is taken off immediately after 25 minutes to kill the animal, the intestinal cavity is opened to separate mesentery, the intestinal canal with the upper end from the pylorus, the lower end to the ileocecal part is cut and taken, the intestinal canal is placed on a tray, the small intestine is slightly pulled to be in a straight line, the length of the intestinal canal is measured as the total length of the small intestine, and the length from the pylorus to the front edge of the ink is measured as the ink propelling.
The small intestine propulsion rate (%) — ink travel distance (cm)/total small intestine length (cm) × 100%.
3. The experimental results are as follows: the small intestine propulsion rate experiments are shown in table 1 below.
TABLE 1 Small intestine Proulsion Rate test results
Note: denotes P < 0.05 compared to placebo; p < 0.01 compared to the blank control.
# denotes P < 0.05 compared to model control; # indicates P < 0.01 compared to model control.
As can be seen from Table 1, compared with the blank control group, the small intestine propulsion rate of the model control group is significantly lower than that of the blank control group (P is less than 0.01), which indicates that the constipation model is successfully established.
The ink propulsion rate of mice in the experiment 1-3 intervention groups, the experiment 1-4 intervention groups, the chrysanthemum powder intervention group and the polydextrose intervention group is obviously higher than that of the model control group (P is less than 0.05); the stachyose dry preparation group and the fructo-oligosaccharide dry preparation group have rising tendency but have no statistical difference. Wherein, compared with the model control group, the ink propulsion rate of the intervention groups of the examples 1 to 3 is very different (P is less than 0.01); the ink propulsion rate of the mice is also remarkably improved in the examples 1-3 compared with the comparative examples 1-4, the inulin dry pre-group, the polydextrose dry pre-group, the stachyose dry pre-group and the fructo-oligosaccharide dry pre-group (P is less than 0.05); the ink propulsion rates of the mice of the comparative examples 1-4 groups were superior to those of the inulin group and the polydextrose group, but the differences were not significant (P > 0.05).
The experimental results show that in the aspect of treating constipation, 4 prebiotics of inulin, polydextrose, stachyose and fructo-oligosaccharide have synergistic effect, and the treatment effect is obviously better than that of one or more prebiotics used alone.
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (9)
1. The composite prebiotics for relaxing bowel is characterized by comprising the following components in parts by weight: 30-80 parts of inulin, 20-60 parts of polydextrose, 2-10 parts of stachyose and 2-10 parts of fructo-oligosaccharide.
2. The composite prebiotic for relaxing bowel according to claim 1, which is composed of the following components in parts by weight: 40-60 parts of inulin, 30-50 parts of polydextrose, 5-10 parts of stachyose and 5-10 parts of fructo-oligosaccharide.
3. The composite prebiotic for relaxing bowel according to claim 1, which is composed of the following components in parts by weight: 48-50 parts of inulin, 30-40 parts of polydextrose, 5-10 parts of stachyose and 5-10 parts of fructo-oligosaccharide.
4. The composite prebiotic for relaxing bowel according to claim 1, which consists of the following components in percentage by weight: 50% of inulin, 30% of polydextrose, 10% of stachyose and 10% of fructo-oligosaccharide; or,
the composite prebiotics capable of relaxing bowel comprises the following components in percentage by weight: 48.4% of inulin, 38.6% of polydextrose, 6.5% of stachyose and 6.5% of fructo-oligosaccharide; or,
the composite prebiotics capable of relaxing bowel comprises the following components in percentage by weight: inulin 50%, polydextrose 40%, stachyose 5% and fructo-oligosaccharide 5%.
5. The composite prebiotic for relaxing bowel according to any one of claims 1 to 3, wherein the total weight thereof is 100 parts.
6. The composite prebiotic for relaxing bowel according to any one of claims 1 to 5,
the inulin content in the inulin is more than or equal to 86 percent; and/or the presence of a gas in the gas,
the content of polydextrose in the polydextrose is more than or equal to 90 percent; and/or the presence of a gas in the gas,
the content of stachyose in the stachyose is more than or equal to 70 percent; and/or the presence of a gas in the gas,
the content of the fructo-oligosaccharide in the fructo-oligosaccharide is more than or equal to 95 percent.
7. The preparation containing the composite prebiotics for relaxing the bowels according to any one of claims 1 to 6, wherein the preparation further contains auxiliary materials and/or additives used in the fields of food and health food; alternatively, the formulation further comprises a pharmaceutically acceptable carrier.
8. The formulation according to claim 7, characterized in that it is a tablet, capsule, granule or tablet candy.
9. Use of the composite prebiotic of any one of claims 1 to 6, or the formulation of claim 7 or 8 in the manufacture of a food or health product or medicament for the treatment of constipation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017106940584 | 2017-08-14 | ||
| CN201710694058 | 2017-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107495383A true CN107495383A (en) | 2017-12-22 |
Family
ID=60692289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710714607.XA Pending CN107495383A (en) | 2017-08-14 | 2017-08-19 | One kind relaxes bowel complex prebiotics and preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107495383A (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108402371A (en) * | 2018-01-19 | 2018-08-17 | 广东润源中天生物科技有限公司 | A kind of prebiotic compositions that suitable person in middle and old age's constipation crowd takes |
| CN108714182A (en) * | 2018-08-17 | 2018-10-30 | 河南夕阳蓝食品科技有限公司 | Bowel relaxing oral liquid and preparation method |
| CN109198356A (en) * | 2018-11-23 | 2019-01-15 | 温友来 | A kind of solid beverage and preparation method thereof with adjusting function of intestinal canal |
| CN109329942A (en) * | 2018-11-08 | 2019-02-15 | 安颖 | A kind of composition and preparation method thereof with adjusting intestinal flora function |
| CN109329947A (en) * | 2018-12-03 | 2019-02-15 | 广州美春堂医药科技有限公司 | Powder and preparation method thereof is directly drunk with the collagen peptide for improving sleep defaecation whitening function |
| CN110881600A (en) * | 2019-10-10 | 2020-03-17 | 人良生物科技（上海）有限公司 | Bowel-clearing and bowel-relaxing solid beverage and preparation method thereof |
| CN111067109A (en) * | 2019-12-27 | 2020-04-28 | 黑龙江省完达山乳业股份有限公司 | Dietary fiber composition and preparation method and application thereof |
| CN112515180A (en) * | 2020-11-18 | 2021-03-19 | 浙江核力欣健药业有限公司 | Composite dietary fiber formula powder and preparation method thereof |
| CN112617204A (en) * | 2020-12-15 | 2021-04-09 | 山东欣瑞文生物科技有限公司 | Arabic gum composition with bowel relaxing and constipation relieving effects |
| CN112617083A (en) * | 2021-01-29 | 2021-04-09 | 赵保国 | Prebiotics solid beverage capable of relaxing bowel and reducing blood sugar and preparation method thereof |
| CN112931883A (en) * | 2021-03-24 | 2021-06-11 | 浙江屯屯麦生物技术开发有限公司 | Prebiotic composition and preparation method and application thereof |
| CN114304653A (en) * | 2022-01-05 | 2022-04-12 | 河南泰利杰生物科技有限公司 | Composition for regulating intestinal microecology and preparation method and application thereof |
| CN114601160A (en) * | 2022-03-15 | 2022-06-10 | 拜斯特药业(广州)有限公司 | Microcapsule with functions of regulating intestinal flora and reducing fat and preparation method and application thereof |
| CN116649583A (en) * | 2023-06-21 | 2023-08-29 | 山东英贝健健康食品有限公司 | Prebiotic composition, beverage and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736266A (en) * | 2005-09-12 | 2006-02-22 | 北京康比特威创体育新技术发展有限公司 | Weight reducing rod |
| CN101366734A (en) * | 2008-06-18 | 2009-02-18 | 辽宁大生药业有限公司 | Synbiotics medicament composition |
| CN103053904A (en) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | Compound functional sugar with function of adjusting intestinal flora |
| CN103932345A (en) * | 2014-05-08 | 2014-07-23 | 英凯营养食品科技（上海）有限公司 | Constipation-relieving drink granules and preparation method thereof |
| CN104642870A (en) * | 2015-02-05 | 2015-05-27 | 骆奇 | Prebiotics composition |
| CN104824511A (en) * | 2015-05-21 | 2015-08-12 | 张利民 | Prebiotics composition |
| CN106509917A (en) * | 2016-11-09 | 2017-03-22 | 易军如 | Composite prebiotics and application thereof |
| CN106539089A (en) * | 2016-11-09 | 2017-03-29 | 易军如 | A kind of complex prebiotics and its application |
-
2017
- 2017-08-19 CN CN201710714607.XA patent/CN107495383A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736266A (en) * | 2005-09-12 | 2006-02-22 | 北京康比特威创体育新技术发展有限公司 | Weight reducing rod |
| CN101366734A (en) * | 2008-06-18 | 2009-02-18 | 辽宁大生药业有限公司 | Synbiotics medicament composition |
| CN103053904A (en) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | Compound functional sugar with function of adjusting intestinal flora |
| CN103932345A (en) * | 2014-05-08 | 2014-07-23 | 英凯营养食品科技（上海）有限公司 | Constipation-relieving drink granules and preparation method thereof |
| CN104642870A (en) * | 2015-02-05 | 2015-05-27 | 骆奇 | Prebiotics composition |
| CN104824511A (en) * | 2015-05-21 | 2015-08-12 | 张利民 | Prebiotics composition |
| CN106509917A (en) * | 2016-11-09 | 2017-03-22 | 易军如 | Composite prebiotics and application thereof |
| CN106539089A (en) * | 2016-11-09 | 2017-03-29 | 易军如 | A kind of complex prebiotics and its application |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108402371A (en) * | 2018-01-19 | 2018-08-17 | 广东润源中天生物科技有限公司 | A kind of prebiotic compositions that suitable person in middle and old age's constipation crowd takes |
| CN108714182A (en) * | 2018-08-17 | 2018-10-30 | 河南夕阳蓝食品科技有限公司 | Bowel relaxing oral liquid and preparation method |
| CN109329942A (en) * | 2018-11-08 | 2019-02-15 | 安颖 | A kind of composition and preparation method thereof with adjusting intestinal flora function |
| CN109198356A (en) * | 2018-11-23 | 2019-01-15 | 温友来 | A kind of solid beverage and preparation method thereof with adjusting function of intestinal canal |
| CN109329947A (en) * | 2018-12-03 | 2019-02-15 | 广州美春堂医药科技有限公司 | Powder and preparation method thereof is directly drunk with the collagen peptide for improving sleep defaecation whitening function |
| CN110881600A (en) * | 2019-10-10 | 2020-03-17 | 人良生物科技（上海）有限公司 | Bowel-clearing and bowel-relaxing solid beverage and preparation method thereof |
| CN111067109A (en) * | 2019-12-27 | 2020-04-28 | 黑龙江省完达山乳业股份有限公司 | Dietary fiber composition and preparation method and application thereof |
| CN112515180A (en) * | 2020-11-18 | 2021-03-19 | 浙江核力欣健药业有限公司 | Composite dietary fiber formula powder and preparation method thereof |
| CN112617204A (en) * | 2020-12-15 | 2021-04-09 | 山东欣瑞文生物科技有限公司 | Arabic gum composition with bowel relaxing and constipation relieving effects |
| CN112617083A (en) * | 2021-01-29 | 2021-04-09 | 赵保国 | Prebiotics solid beverage capable of relaxing bowel and reducing blood sugar and preparation method thereof |
| CN112931883A (en) * | 2021-03-24 | 2021-06-11 | 浙江屯屯麦生物技术开发有限公司 | Prebiotic composition and preparation method and application thereof |
| CN114304653A (en) * | 2022-01-05 | 2022-04-12 | 河南泰利杰生物科技有限公司 | Composition for regulating intestinal microecology and preparation method and application thereof |
| CN114601160A (en) * | 2022-03-15 | 2022-06-10 | 拜斯特药业(广州)有限公司 | Microcapsule with functions of regulating intestinal flora and reducing fat and preparation method and application thereof |
| CN116649583A (en) * | 2023-06-21 | 2023-08-29 | 山东英贝健健康食品有限公司 | Prebiotic composition, beverage and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107495383A (en) | One kind relaxes bowel complex prebiotics and preparation method and application | |
| Lomax et al. | Prebiotics, immune function, infection and inflammation: a review of the evidence | |
| CN106954847A (en) | Ferment probiotic composition with function of relaxing bowel, using and process preparation | |
| CN107467677A (en) | A kind of compound nutritional product for relaxing bowel, maintaining intestinal health and preparation method and application | |
| CN105725219B (en) | A kind of composition of containing water soluble dietary fiber and Water insoluble dietary fiber | |
| JP2010120945A (en) | Inulin product with improved nutritional property | |
| JPH0126A (en) | Mixture for the treatment of hypercholesterolemia | |
| JP5992654B2 (en) | Composition for intestinal regulation and / or improvement of bowel movement | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| NO320546B1 (en) | Prebiotic combination products | |
| JPH05255097A (en) | Liquid composition | |
| CN116549494B (en) | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof | |
| CN109645501A (en) | A kind of galactooligosaccharide composition and its application of defaecation and reduction flatulence | |
| Tabrizi et al. | Functional laxative foods: Concepts, trends and health benefits | |
| JP4113242B1 (en) | Gastrointestinal symptoms | |
| CN108887688A (en) | A kind of multifarious dietary fiber and preparation method thereof | |
| CN112806577B (en) | Prebiotic probiotic synergistic combinations for butyric acid production | |
| CN108245531A (en) | It is a kind of to improve gastrointestinal function, the anti-composition to treat constipation | |
| WO2014134830A1 (en) | Edible composition, food product comprising same, and preparation method for the food product | |
| CN108245530A (en) | A kind of composition with functions of loosening bowel relieving constipation and preparation method thereof and purposes | |
| JP4071818B1 (en) | sweetener | |
| CN104757549B (en) | One kind relaxes bowel composition | |
| CN101589806A (en) | A kind of solid low-energy food that is rich in dietary fiber and polyethylene glycol and preparation method thereof | |
| CN101167812A (en) | 'Fengliaochangweikang' dispersible tablet and preparation method thereof | |
| Abbasalizadeh et al. | Review of Constipation Treatment Methods with Emphasis on Laxative Foods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |